![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Teva Earns First FDA Approval for Generic Drug for Major Depressive Disorder
Teva Earns First FDA Approval for Generic Drug for Major Depressive Disorder
![Teva.gif](https://www.fdanews.com/ext/resources/test/Drug-Images2/Teva.gif?t=1579040955&width=430)
October 10, 2019
The FDA approved Teva‘s vilazodone hydrochloride tablets in 10 mg, 20 mg and 40 mg for treatment of major depressive disorder (MDD).
The Teva product is a generic of Allergan’s Viibryd tablets, which the agency approved in 2011 for treating MDD in adults.
The approval marks the agency’s 82nd first-time generic approval in 2019 and the first generic approved for MDD.
Upcoming Events
-
21Oct